发布求助
文献互助 智能选刊 最新文献

Leukemia Research Reports最新文献

筛选
英文 中文
Unveiling prognosis in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax through novel risk stratification 通过新的风险分层揭示低甲基化药物和venetoclax治疗急性髓系白血病患者的预后
IF 0.9
Leukemia Research Reports Pub Date : 2025-01-01 Epub Date: 2025-10-11 DOI: 10.1016/j.lrr.2025.100550
Jiajia Sun, Zhiping Guo
{"title":"Unveiling prognosis in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax through novel risk stratification","authors":"Jiajia Sun,&nbsp;Zhiping Guo","doi":"10.1016/j.lrr.2025.100550","DOIUrl":"10.1016/j.lrr.2025.100550","url":null,"abstract":"<div><div>Several genetic risk classification systems based on response to older acute myeloid leukemia patients treated with less-intensive regimens, especially venetoclax (VEN) + hypomethylating agent (HMA), are proposed recently. VEN+HMA improved the outcome of cytogenetic adverse-risk AML, AML with some of MR mutations and/or clonal hematopoiesis (CH) related mutations. <em>DNMT3A</em><sup>mut</sup>, <em>IDH1/2</em><sup>mut</sup> and <em>NPM1</em><sup>mut</sup> were defined as “VEN sensitive mutations”. <em>DDX41</em><sup>mut</sup> is identified as a particularly favorable-risk group. Even multi-hit <em>TP53</em> status did not negatively affect overall survival (OS) of <em>DDX41</em>-mutants. Signaling gene mutations (<em>FLT3-</em>ITD<sup>pos</sup> and <em>K/NRAS</em><sup>mut</sup>) are classified as intermediate risk, consistent with their biological associations as mediators of VEN resistance.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"24 ","pages":"Article 100550"},"PeriodicalIF":0.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145320236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Le lymphome cutanée primitif diffus à grandes cellules B : à propos d’un cas Primary cutaneous diffuse large B-cell lymphoma: a case report 原发性皮肤弥漫性大B细胞淋巴瘤：病例报告
IF 0.9
Leukemia Research Reports Pub Date : 2025-01-01 Epub Date: 2025-08-08 DOI: 10.1016/j.lrr.2025.100538
Mustapha Mechtoune , Fatima Zahra Lahlimi , Illias Tazi , Hanane Rais , Houda Jouihri , Mohammed el Fadli
{"title":"Le lymphome cutanée primitif diffus à grandes cellules B : à propos d’un cas Primary cutaneous diffuse large B-cell lymphoma: a case report","authors":"Mustapha Mechtoune ,&nbsp;Fatima Zahra Lahlimi ,&nbsp;Illias Tazi ,&nbsp;Hanane Rais ,&nbsp;Houda Jouihri ,&nbsp;Mohammed el Fadli","doi":"10.1016/j.lrr.2025.100538","DOIUrl":"10.1016/j.lrr.2025.100538","url":null,"abstract":"<div><div>The association of cutaneous B-cell lymphoma and dermatofibrosarcoma is exceptional. We report the case of a 44-year-old patient with a history of Darier-Ferrand dermatofibrosarcoma who presented with cutaneous B-cell lymphoma characterized by large atypical skin lesions with an aggressive course. The patient was treated with a combination of RCHOP-type chemotherapy and surgical treatment. We shed light on this very rare association whose prognosis depends on early diagnosis and adequate management.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"24 ","pages":"Article 100538"},"PeriodicalIF":0.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145157328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rapid development of Philadelphia chromosome-negative AML in a CML patient with sustained major molecular response to tyrosine kinase inhibitor therapy 在对酪氨酸激酶抑制剂治疗持续主要分子反应的CML患者中，费城染色体阴性AML的快速发展
IF 0.9
Leukemia Research Reports Pub Date : 2025-01-01 Epub Date: 2025-08-21 DOI: 10.1016/j.lrr.2025.100536
Huan Liu , Yunxia Sun , Liangliang Li , Yurong Zhang , Yaxiong Zhou , Pengyun Zeng , Lingling Yue
{"title":"Rapid development of Philadelphia chromosome-negative AML in a CML patient with sustained major molecular response to tyrosine kinase inhibitor therapy","authors":"Huan Liu ,&nbsp;Yunxia Sun ,&nbsp;Liangliang Li ,&nbsp;Yurong Zhang ,&nbsp;Yaxiong Zhou ,&nbsp;Pengyun Zeng ,&nbsp;Lingling Yue","doi":"10.1016/j.lrr.2025.100536","DOIUrl":"10.1016/j.lrr.2025.100536","url":null,"abstract":"<div><div>The use of TKIs has significantly improved the prognosis of CML. However, a small subset of patients still experience poor outcomes. We present a rare case of Ph-AML following a diagnosis of CML. The patient achieved CCyR and MMR after 4 months of nilotinib therapy, with sustained deep remission for 3 years. Unexpectedly, the disease developed rapidly to AML. Further investigations revealed the emergence of CCA/Ph- and gene mutations. We retrospectively analyzed previous CML patients with <em>BCR::ABL1</em> and Ph-negative status in blast crisis from our database and conducted a comprehensive review of the relevant literature.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"24 ","pages":"Article 100536"},"PeriodicalIF":0.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144903128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Asciminib and inotuzumab ozogamicin: a new combination for highly refractory Ph-positive B-cell acute lymphoblastic leukemia 阿西米尼和inotuzumab ozogamicin：一种治疗高度难治性ph阳性b细胞急性淋巴细胞白血病的新组合
IF 0.9
Leukemia Research Reports Pub Date : 2025-01-01 Epub Date: 2025-09-16 DOI: 10.1016/j.lrr.2025.100546
Aneta Strumilowska , Katherine Devitt , Joanna Conant , Juli-Anne Gardner , Ashley Volaric , Neel Hegde , Diego Adrianzen-Herrera
{"title":"Asciminib and inotuzumab ozogamicin: a new combination for highly refractory Ph-positive B-cell acute lymphoblastic leukemia","authors":"Aneta Strumilowska ,&nbsp;Katherine Devitt ,&nbsp;Joanna Conant ,&nbsp;Juli-Anne Gardner ,&nbsp;Ashley Volaric ,&nbsp;Neel Hegde ,&nbsp;Diego Adrianzen-Herrera","doi":"10.1016/j.lrr.2025.100546","DOIUrl":"10.1016/j.lrr.2025.100546","url":null,"abstract":"","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"24 ","pages":"Article 100546"},"PeriodicalIF":0.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145094824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-World Efficacy and Safety of Gemtuzumab Ozogamycin (GO) and 3 + 7 regimen in fit newly diagnosed Acute Myeloid Leukemia (AML) patients. A Retrospective multicenter study of “Rete Ematologica Pugliese” (REP) Gemtuzumab Ozogamycin （GO）和3 + 7方案在适合新诊断的急性髓性白血病（AML）患者中的实际疗效和安全性“Pugliese Rete emat”（REP）的多中心回顾性研究
IF 0.7
Leukemia Research Reports Pub Date : 2025-01-01 Epub Date: 2025-06-28 DOI: 10.1016/j.lrr.2025.100525
M. Dargenio , C. Buquicchio , D. Pastore , L. Aprile , L. Ciuffreda , G. Greco , M. Delia , V. Federico , MP. Fina , D. Seripa , R. Matera , G. Tarantini , A. Maggi , L. Melillo , V. Pavone , P. Musto , G. Specchia , N. Di Renzo
{"title":"Real-World Efficacy and Safety of Gemtuzumab Ozogamycin (GO) and 3 + 7 regimen in fit newly diagnosed Acute Myeloid Leukemia (AML) patients. A Retrospective multicenter study of “Rete Ematologica Pugliese” (REP)","authors":"M. Dargenio ,&nbsp;C. Buquicchio ,&nbsp;D. Pastore ,&nbsp;L. Aprile ,&nbsp;L. Ciuffreda ,&nbsp;G. Greco ,&nbsp;M. Delia ,&nbsp;V. Federico ,&nbsp;MP. Fina ,&nbsp;D. Seripa ,&nbsp;R. Matera ,&nbsp;G. Tarantini ,&nbsp;A. Maggi ,&nbsp;L. Melillo ,&nbsp;V. Pavone ,&nbsp;P. Musto ,&nbsp;G. Specchia ,&nbsp;N. Di Renzo","doi":"10.1016/j.lrr.2025.100525","DOIUrl":"10.1016/j.lrr.2025.100525","url":null,"abstract":"<div><div>Gemtuzumab Ozogamicin, a monoclonal antibody targeting CD33, linked to calicheamicin, is approved in combination with “3 + 7″ for the treatment of patients with de novo CD33 positive AML. The aim of study was to evaluate the outcome of patients receiving 3 + 7 plus GO as front-line therapy outside clinical trials. Between March 2020 and February 2023, 34 consecutive fit CD33+ AML patients, median age 54.5 years (range, 25–75) were treated. This study confirms the efficacy and toxicity data reported in clinical trials, highlighting the feasibility of GO based chemotherapy also in patients older than 60 years and as a bridge to allo-HSCT.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"24 ","pages":"Article 100525"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144523811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The synergistic effect of 2-deoxy-D-glucose and cytarabine on mitochondria of stem-like cells derived from KG1-a 2-脱氧-d -葡萄糖和阿糖胞苷对KG1-a源性干细胞线粒体的协同作用
IF 0.9
Leukemia Research Reports Pub Date : 2025-01-01 Epub Date: 2025-08-11 DOI: 10.1016/j.lrr.2025.100537
Sona Rezaei , Mohammad Mohammadzadeh-Vardin , Keyvan Amirshahrokhi , Mojtaba Amani
{"title":"The synergistic effect of 2-deoxy-D-glucose and cytarabine on mitochondria of stem-like cells derived from KG1-a","authors":"Sona Rezaei ,&nbsp;Mohammad Mohammadzadeh-Vardin ,&nbsp;Keyvan Amirshahrokhi ,&nbsp;Mojtaba Amani","doi":"10.1016/j.lrr.2025.100537","DOIUrl":"10.1016/j.lrr.2025.100537","url":null,"abstract":"<div><div>Acute myeloid leukemia (AML) often relapses post-chemotherapy due to leukemia stem cells (LSCs), which rely on mitochondria for energy, ROS regulation, and apoptosis. Targeting mitochondrial pathways may overcome LSC resistance. This study evaluated Cytarabine (Ara-C), 2-Deoxy-d-Glucose (2-DG), and their combination on AML-derived KG1-a cells using MTT assays, showing reduced viability with combined treatment. The Magnetic sorting isolated CD34+ (stem-like) and CD34- cells. Flow cytometry revealed increased ROS and decreased mitochondrial membrane potential (MMP) in KG1-a and CD34+ cells with 2-DG and Ara-C, suggesting a promising strategy to target resistant LSCs in AML therapy.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"24 ","pages":"Article 100537"},"PeriodicalIF":0.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144863976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Baseline erythropoietin level predicts Luspatercept response in Chinese patients with myelodysplastic syndrome: a propensity score-matched analysis 基线促红细胞生成素水平预测中国骨髓增生异常综合征患者的Luspatercept反应：倾向评分匹配分析
IF 0.7
Leukemia Research Reports Pub Date : 2025-01-01 Epub Date: 2025-07-24 DOI: 10.1016/j.lrr.2025.100532
Doudou Chang , Junyan Zhang , Meiling Zhao , Xialin Zhang , Jia Wei , Ruijuan Zhang
{"title":"Baseline erythropoietin level predicts Luspatercept response in Chinese patients with myelodysplastic syndrome: a propensity score-matched analysis","authors":"Doudou Chang ,&nbsp;Junyan Zhang ,&nbsp;Meiling Zhao ,&nbsp;Xialin Zhang ,&nbsp;Jia Wei ,&nbsp;Ruijuan Zhang","doi":"10.1016/j.lrr.2025.100532","DOIUrl":"10.1016/j.lrr.2025.100532","url":null,"abstract":"<div><h3>Background</h3><div>Luspatercept is a novel erythroid maturation agent approved for treating transfusion-dependent anemia in myelodysplastic syndrome (MDS). However, predictive biomarkers and real-world data in Asian populations remain limited.</div></div><div><h3>Methods</h3><div>We conducted a retrospective cohort study of 66 MDS patients from two Chinese centers, including 22 patients treated with luspatercept and 44 matched controls. Propensity score matching (1:2) was used to adjust for age, sex, risk category, baseline hemoglobin, transfusion burden, and erythropoietin (EPO) levels. Primary endpoints were red blood cell transfusion independence (RBC-TI) ≥8 weeks and hematologic improvement–erythroid (HI-E).</div></div><div><h3>Results</h3><div>By week 12, 54.5 % of luspatercept-treated patients achieved RBC-TI, compared to 29.5 % in the control group (<em>P</em> &lt; 0.05). Patients with baseline EPO &lt;500 IU/mL had higher RBC-TI rates than those with EPO ≥500 IU/mL (63.6 % vs. 45.5 %). Multivariate analysis identified baseline EPO &lt;500 IU/mL as an independent predictor of response (OR=2.36, 95 % CI: 1.24–4.52, <em>P</em> = 0.008). Safety was acceptable, with no treatment discontinuation due to adverse events.</div></div><div><h3>Conclusion</h3><div>This first matched real-world study of luspatercept in Chinese MDS patients confirms its efficacy in reducing transfusion needs and identifies baseline erythropoietin level as a clinically meaningful predictor of response. These findings support the integration of EPO-guided selection in personalized treatment strategies.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"24 ","pages":"Article 100532"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144712931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of non-coding RNAs on resistance to imatinib in chronic myelogenous leukemia 非编码rna对慢性粒细胞白血病伊马替尼耐药的影响
IF 0.7
Leukemia Research Reports Pub Date : 2025-01-01 Epub Date: 2025-07-10 DOI: 10.1016/j.lrr.2025.100529
Fatemeh Ensafi Talemi , Soudeh Ghafouri-Fard
{"title":"Impact of non-coding RNAs on resistance to imatinib in chronic myelogenous leukemia","authors":"Fatemeh Ensafi Talemi ,&nbsp;Soudeh Ghafouri-Fard","doi":"10.1016/j.lrr.2025.100529","DOIUrl":"10.1016/j.lrr.2025.100529","url":null,"abstract":"<div><div>Imatinib is approved as the first-line treatment for newly diagnosed chronic myelogenous leukemia (CML). In spite of profound response in the majority of patients, resistance occurs in a subgroup of CML cases. Recently, it has been demonstrated that different classes of non-coding RNAs can modulate response to this tyrosine kinase inhibitor. Recognition of the role of these transcripts in this process not only expands our knowledge about the molecular mechanisms of imatinib resistance, but also provides novel strategies for combating this phenotype. The current review summarizes the role of non-coding RNAs in this process and suggests novel candidates for further studies in this field to enhance therapeutic response to imatinib.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"24 ","pages":"Article 100529"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144605228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acute myeloid leukemia: A rare cause of acquired isolated factor VII deficiency 急性髓性白血病：获得性分离因子VII缺乏的罕见原因
IF 0.7
Leukemia Research Reports Pub Date : 2025-01-01 Epub Date: 2025-05-17 DOI: 10.1016/j.lrr.2025.100516
Zaineb Mlayah, Haifa Hafsa, Alaa Ghorbel, Nader Slama, Sara Boukhris, Mohamed-Adnene Laatiri
{"title":"Acute myeloid leukemia: A rare cause of acquired isolated factor VII deficiency","authors":"Zaineb Mlayah,&nbsp;Haifa Hafsa,&nbsp;Alaa Ghorbel,&nbsp;Nader Slama,&nbsp;Sara Boukhris,&nbsp;Mohamed-Adnene Laatiri","doi":"10.1016/j.lrr.2025.100516","DOIUrl":"10.1016/j.lrr.2025.100516","url":null,"abstract":"<div><h3>Background</h3><div>Acquired factor VII deficiency remains a rare pathology. Only 5 prior reported cases of aFVIID associated with acute myeloid leukemia (AML) have been described in the literature. Despite the rarity of these occurrences, these cases hold significant clinical and scientific implications given the need to understand the physopathology and to establish a therapeutic protocol ensuring better management.</div></div><div><h3>Case presentation</h3><div>A 38-year-old Arab male with AML was diagnosed at our Department of Clinical Hematology. The initial coagulation panel at admission revealed slightly low prothrombin ratio (PT) of 56 %, while the international normalized ratio (INR) and partial thromboplastin time (PTT) were within normal. Prothrombin complex coagulation factor dosing (PCCFD) confirmed an isolated reduction in the FVII in repeated samples, indicating an isolated deficiency. This patient did not present severe bleeding syndrome and had received conventional chemotherapy (cytarabine (Cytarabine)+ idarubicin). The evolution was marked by cytological remission (CR) with correction of coagulation disorders.</div></div><div><h3>Conclusion</h3><div>In conclusion, the intricate relationship between isolated aFVIID and AML remains mysterious. Researchers are essential to unravel the intricacies of this rare hematological condition. Further exploration into the molecular mechanisms, prognostic implications, and evolving treatment modalities is crucial to enhance the precision and efficacy of therapeutic interventions.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"23 ","pages":"Article 100516"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144124486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Trans-differentiation of plasma cell neoplasm to acute myeloid leukemia with monocytic features: Case report of divergent phenotype with identical genotype 浆细胞肿瘤向具有单核细胞特征的急性髓系白血病的反分化：基因型相同但表型不同的病例报告
IF 0.7
Leukemia Research Reports Pub Date : 2025-01-01 Epub Date: 2025-02-17 DOI: 10.1016/j.lrr.2025.100504
Saja Asakrah , Kristin K. Deeb , Nikolaos Papadantonakis , George Deeb
{"title":"Trans-differentiation of plasma cell neoplasm to acute myeloid leukemia with monocytic features: Case report of divergent phenotype with identical genotype","authors":"Saja Asakrah ,&nbsp;Kristin K. Deeb ,&nbsp;Nikolaos Papadantonakis ,&nbsp;George Deeb","doi":"10.1016/j.lrr.2025.100504","DOIUrl":"10.1016/j.lrr.2025.100504","url":null,"abstract":"<div><div>Myeloid malignancies following treatment for plasma cell neoplasms (PCN) are infrequent but is a serious complication, often exhibiting complex karyotype and <em>TP53</em> mutations. Plasma cell myeloma lineage switch to a myeloid malignancy with evident clonal relatedness is seldomly reported. Here, we report a unique case of acute myeloid leukemia with monocytic differentiation that shares clonal features with an antecedent plasma cell myeloma with t(4;14)(<em>FGFR3::IGH</em>). This phenomenon differs from therapy-related myeloid neoplasm arising from an unrelated clone and underscores the need to elucidate the role of mutations in pathways such as MAPK (e.g., <em>BRAF</em> and <em>KRAS</em>) into lineage plasticity.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"23 ","pages":"Article 100504"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143479979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信
小红书